Because IGFBP2 is not expressed by normal HSCs but highly expressed by leukemia stem cells and differentiated leukemia cells, it is desirable to develop anti-IGFBP2 therapy that may effectively induce apoptosis and block mobilization of leukemia cells including leukemia stem cells with minimal toxicity to normal HSCs. The gene discussed is IGFBP2; the disease is leukemia.